Bone adaptation optimizes mass and structure, but the mechano-response is already reduced at maturation. Downregulation of sclerostin was believed to be a mandatory step in mechano-adaptation, but in young mice it was shown that load-induced formation can occur independent of sclerostin, a product of the Sost gene. We hypothesized that the bone formation and resorption response to loading is not affected by Sost deficiency, but is age-specific. Our findings indicate that the anabolic response to in vivo tibial loading was reduced at maturation in Sost Knockout (KO) and littermate control (LC) mice. Age affected all anabolic and catabolic parameters and altered Sost and Wnt target gene expression. While load-induced cortical resorption was s...
A new therapeutic option to treat osteoporosis is focused on Wnt signaling and its inhibitor scleros...
SCLEROSTIN (Sost) is expressed predominantly in osteocytes acting as a negative regulator of bone fo...
SCLEROSTIN (Sost) is expressed predominantly in osteocytes acting as a negative regulator of bone fo...
Bone adaptation optimizes mass and structure, but the mechano-response is already reduced at matura...
Loss-of-function mutations in the Sost gene lead to high bone mass phenotypes. Pharmacological inhib...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the Sost gene, is a Wnt-inhibitor and thus negatively regulates bone accrua...
Sclerostin, the Wnt signaling antagonist encoded by the Sost gene, is secreted by osteocytes and inh...
Mechanical loading is the primary functional determinant of bone mass and architecture, and osteocyt...
AbstractMechanical loading is the primary functional determinant of bone mass and architecture, and ...
Sclerostin, encoded by the Sost gene, is an important negative regulator of bone formation that has ...
A new therapeutic option to treat osteoporosis is focused on Wnt signaling and its inhibitor scleros...
SCLEROSTIN (Sost) is expressed predominantly in osteocytes acting as a negative regulator of bone fo...
SCLEROSTIN (Sost) is expressed predominantly in osteocytes acting as a negative regulator of bone fo...
Bone adaptation optimizes mass and structure, but the mechano-response is already reduced at matura...
Loss-of-function mutations in the Sost gene lead to high bone mass phenotypes. Pharmacological inhib...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the <i>Sost</i> gene, is a Wnt-inhibitor and thus negatively regulates bone...
Sclerostin, a product of the Sost gene, is a Wnt-inhibitor and thus negatively regulates bone accrua...
Sclerostin, the Wnt signaling antagonist encoded by the Sost gene, is secreted by osteocytes and inh...
Mechanical loading is the primary functional determinant of bone mass and architecture, and osteocyt...
AbstractMechanical loading is the primary functional determinant of bone mass and architecture, and ...
Sclerostin, encoded by the Sost gene, is an important negative regulator of bone formation that has ...
A new therapeutic option to treat osteoporosis is focused on Wnt signaling and its inhibitor scleros...
SCLEROSTIN (Sost) is expressed predominantly in osteocytes acting as a negative regulator of bone fo...
SCLEROSTIN (Sost) is expressed predominantly in osteocytes acting as a negative regulator of bone fo...